US2010257617A1PendingUtilityA1

Transgenic animals comprising gene fusions

52
Assignee: UNIV MICHIGANPriority: Sep 12, 2005Filed: Feb 21, 2007Published: Oct 7, 2010
Est. expirySep 12, 2025(expired)· nominal 20-yr term from priority
Inventors:Chinnaiyan ArulBharathi LaxmanScott TomlinsRohit Mera
G01N 33/57555C12Q 2600/106C12Q 2600/158C12N 2310/11C12N 9/6445C12N 2310/14C12N 15/113A01K 2267/0331Y10S435/81C12Q 2600/118C12Q 2600/136A01K 67/0275C07K 2319/00C07K 14/82A01K 2217/072A01K 2227/105C12Q 1/6886A01K 2217/206C12N 9/6424C12Q 2600/156C12Q 2600/112
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusion nucleic acids and transgenic animals comprising recurrent gene fusion nucleic acids.

Claims

exact text as granted — not AI-modified
1 . A transgenic animal comprising a genome that comprises a heterologous gene, wherein said heterologous gene comprises a gene fusion having a 5′ portion from a transcriptional regulatory region of an androgen regulated gene and a 3′ portion from an ETS family member gene. 
     
     
         2 . The transgenic animal of  claim 1 , wherein the androgen regulated gene is selected from the group consisting of TMPRSS2 and PSA. 
     
     
         3 . The transgenic animal of  claim 2 , wherein the transcriptional regulatory region of the androgen regulated gene comprises a promoter region of the androgen regulated gene. 
     
     
         4 . The transgenic animal of  claim 3 , wherein the promoter region of the androgen regulated gene comprises an androgen response element (ARE) of the androgen regulated gene. 
     
     
         5 . The transgenic animal of  claim 1 , wherein the ETS family member gene is selected from the group consisting of ERG, ETV1 (ER81), FLI1, ETS1, ETS2, ELK1, ETV6 (TEL1), ETV7 (TEL2), GABPα, ELF1, ETV4 (E1AF; PEA3), ETV5 (ERM), ERF, PEA3/E1AF, PU.1, ESE1/ESX, SAP1 (ELK4), ETV3 (METS), EWS/FLI1, ESE1, ESE2 (ELF5), ESE3, PDEF, NET (ELK3; SAP2), NERF (ELF2), and FEV. 
     
     
         6 . The transgenic animal of  claim 1 , wherein said gene fusions are selected from the group consisting of SEQ ID NOs: 269-306. 
     
     
         7 . The transgenic animal of  claim 1 , wherein said animal is a mouse. 
     
     
         8 . The transgenic animal of  claim 1 , wherein said animal displays symptoms of prostatic intraepithelial neoplasia. 
     
     
         9 . The transgenic animal of  claim 1 , wherein said animal displays symptoms of prostate cancer.

Join the waitlist — get patent alerts

Track US2010257617A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.